Martin Boegemann

3.8k total citations
90 papers, 1.4k citations indexed

About

Martin Boegemann is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Martin Boegemann has authored 90 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pulmonary and Respiratory Medicine, 34 papers in Radiology, Nuclear Medicine and Imaging and 30 papers in Oncology. Recurrent topics in Martin Boegemann's work include Prostate Cancer Treatment and Research (54 papers), Radiopharmaceutical Chemistry and Applications (29 papers) and Renal cell carcinoma treatment (19 papers). Martin Boegemann is often cited by papers focused on Prostate Cancer Treatment and Research (54 papers), Radiopharmaceutical Chemistry and Applications (29 papers) and Renal cell carcinoma treatment (19 papers). Martin Boegemann collaborates with scholars based in Germany, United States and France. Martin Boegemann's co-authors include Andres Jan Schrader, Kambiz Rahbar, Laura‐Maria Krabbe, Michael Schäfers, Katrin Schlack, Thomas Schnoeller, Katharina Kessel, Julie Steinestel, Robert Seifert and Matthias Weckesser and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Martin Boegemann

79 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Boegemann Germany	19	1.2k	630	430	388	228	90	1.4k
Rosa Nadal United States	18	1.4k 1.2×	520 0.8×	572 1.3×	523 1.3×	472 2.1×	48	1.9k
Maria De Santis Austria	9	1.2k 1.1×	474 0.8×	288 0.7×	253 0.7×	201 0.9×	25	1.4k
Mario Eisenberger United States	14	981 0.8×	366 0.6×	398 0.9×	247 0.6×	234 1.0×	32	1.5k
Shinta Cheng United States	13	1.3k 1.1×	537 0.9×	441 1.0×	432 1.1×	257 1.1×	39	1.6k
Martin Bögemann Germany	22	1.6k 1.4×	1.2k 1.9×	510 1.2×	327 0.8×	236 1.0×	86	1.9k
Chandler H. Park United States	8	1.2k 1.0×	1.1k 1.7×	602 1.4×	198 0.5×	186 0.8×	20	1.7k
K.N. Chi Canada	17	1.2k 1.0×	462 0.7×	703 1.6×	405 1.0×	397 1.7×	76	1.6k
Erik Briers Belgium	5	1.1k 1.0×	445 0.7×	233 0.5×	223 0.6×	156 0.7×	7	1.3k
Diletta Bianchini United Kingdom	22	1.6k 1.4×	755 1.2×	659 1.5×	768 2.0×	356 1.6×	68	2.1k
Benjamin L. Maughan United States	22	1.4k 1.2×	294 0.5×	915 2.1×	707 1.8×	541 2.4×	167	2.1k

Countries citing papers authored by Martin Boegemann

Since Specialization

Citations

This map shows the geographic impact of Martin Boegemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Boegemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Boegemann more than expected).

Fields of papers citing papers by Martin Boegemann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Boegemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Boegemann. The network helps show where Martin Boegemann may publish in the future.

Co-authorship network of co-authors of Martin Boegemann

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Boegemann. A scholar is included among the top collaborators of Martin Boegemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Boegemann. Martin Boegemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shore, Neal D., Amee Morgans, Martin Boegemann, et al.. (2025). Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis. European Journal of Cancer. 223. 115513–115513.

Garje, Rohan, Bernadett Szabados, Colleen Peyton, et al.. (2025). LBA112 Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results. Annals of Oncology. 36. S1652–S1653.

Wallis, Christopher J.D., Sara Ekberg, Alicia K. Morgans, et al.. (2025). Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. European Urology Oncology.

Shore, Neal D., Alicia K. Morgans, Noman Paracha, et al.. (2024). A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?. Journal of Clinical Oncology. 42(4_suppl). 324–324.

Modlin, Irvin M., Mark Kidd, Ignat Drozdov, et al.. (2024). Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood. The Prostate. 84(9). 850–865. 10 indexed citations

Roubaud, Guilhem, Gerhardt Attard, Martin Boegemann, et al.. (2024). Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. European Journal of Cancer. 209. 114183–114183. 2 indexed citations

Omlin, Aurelius, Richard Cathomas, Gunhild von Amsberg, et al.. (2023). Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(10). 1887–1893. 6 indexed citations

Oudard, Stéphane, Raffaele Ratta, Éric Voog, et al.. (2023). 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial. Annals of Oncology. 34. S978–S979. 1 indexed citations

Schlack, Katrin, Laura‐Maria Krabbe, Kambiz Rahbar, et al.. (2021). ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. Translational Andrology and Urology. 10(10). 3986–3999. 8 indexed citations

10.

Romano, Emanuela, Srikala S. Sridhar, Michael Kolinsky, et al.. (2020). 620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update. Annals of Oncology. 31. S512–S513. 3 indexed citations

11.

Bernemann, Christof, Julie Steinestel, Xin Chen, et al.. (2019). Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. Clinical Cancer Research. 25(13). 3856–3864. 15 indexed citations

12.

Lebentrau, Steffen, Ingmar Wolff, Luis A. Kluth, et al.. (2019). Kenntnisse von deutschsprachigen Urologen zur Häufigkeit der Assoziation des Peniskarzinoms mit dem Humanen Papillomavirus – Survey-Ergebnisse der European PROspective Penile Cancer Study (E-PROPS). Aktuelle Urologie. 53(5). 461–467. 4 indexed citations

13.

Eminağa, Okyaz, et al.. (2019). Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer. Health Informatics Journal. 26(2). 945–962. 12 indexed citations

14.

Bedke, Jens, Manfred Welslau, Martin Boegemann, et al.. (2017). Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape. Annals of Oncology. 28. v318–v319. 1 indexed citations

15.

Rahbar, Kambiz, Martin Boegemann, Anna Yordanova, et al.. (2017). PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. European Journal of Nuclear Medicine and Molecular Imaging. 45(1). 12–19. 122 indexed citations

16.

Boegemann, Martin & Laura‐Maria Krabbe. (2016). Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer. Mini-Reviews in Medicinal Chemistry. 20(12). 1133–1152. 9 indexed citations

17.

Schlack, Katrin, Martin Boegemann, Julie Steinestel, Andres Jan Schrader, & Laura‐Maria Krabbe. (2016). The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Review of Anticancer Therapy. 16(3). 255–271. 27 indexed citations

18.

Rahbar, Kambiz, Axel Bode, Matthias Weckesser, et al.. (2016). Radioligand Therapy with Lu-177-PSMA-617 may improve survival in Patients with Metastatic Prostate Cancer. 57. 142–142. 1 indexed citations

19.

Boegemann, Martin, et al.. (2015). Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). Current Cancer Drug Targets. 15(3). 243–255. 14 indexed citations

20.

Eminağa, Okyaz, Mahmoud Abbas, Elke Eltze, et al.. (2015). Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens. Urology. 86(4). 798–804. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact